
Dr. Robert Fremeau
Founder and CEO
Experienced R&D; leader with 20+ years of experience in academia and industry.
Stem cell and brain organoid pioneer
Dr. Muotri is a professor at the Departments of Pediatrics and Cellular and Molecular Medicine at University of California San Diego, where he is also the co-director of the new Gene Therapy Initiative, and the director of the Stem Cell Program and Archealization Center. Dr. Muotri earned a B.Sc. in biological sciences from the State University of Campinas in 1995 and a Ph.D. in genetics in 2001 from University of Sao Paulo, in Brazil. He moved to the Salk Institute as a Pew Latin America Fellow in 2002 for a postdoctoral training in neuroscience and stem cell biology. His research focuses on brain evolution and modeling neurological diseases using human-induced pluripotent stem cells and brain organoids. He has received several awards, including the prestigious NIH Director’s New Innovator Award, the Brain & Behavior Research Foundation’s NARSAD Young Investigator Grant, the Emerald Foundation Young Investigator Award, the Surugadai Award, Rock Star of Innovation, the NIH EUREKA Award, and two Telly Awards for Excellence in Science Communication, among several others.

Founder and CEO
Experienced R&D; leader with 20+ years of experience in academia and industry.

Co-founder and CSO
Neurobiologist with 5+ years of experience in cortical organoid disease models and applications of bioinformatics/machine learning in drug discovery.

Experienced biotech C-suite officer
Current BOD, SAB member, and former CEO at ADRx, Inc.

Innovative medicinal chemist
30+ years of drug discovery and development experience.

Computational biology, software development, and genetics expertise
Professor of Genetics, Genomic Sciences, and Neuroscience, Mount Sinai Icahn School of Medicine; member of the Icahn Genomics Institute.

Business development professional with deep commercial experience
19+ years building new markets and driving paradigm-shifting tools into biopharma, government, and academic organizations.
Talk to us about our precision neuroscience platform, our Parkinson’s disease program, or working with the BrainStorm team.